Kanarb recorded a total prescription cost of 14.2 billion won, beating Olmetec which maintained no.1 in antihypertensive single drug sector

On August 13, according to the analysis result of prescription performance of antihypertensive single drug regimen sector in the first half of this year, Kanarb recorded a total prescription cost of 14.2 billion won, beating Olmetec (14 billion won) which maintained no.1 in single drug regimen sector.

Kanarb ranked no.1 in clinic prescription sector in last November, ranked first leading produ...